brerwallabi
The Oracle
- Joined
- 5 July 2004
- Posts
- 1,044
- Reactions
- 795
Re: NORWOOD ABBEY NAL - good results
Sorry pal, Why?
Looked b4 tough if your caught.
Sorry pal, Why?
Looked b4 tough if your caught.
NAL - Norwood Abbey
- Thread starter tarnor
- Start date
-
- Tags
- nal norwood abbey
Re: NORWOOD ABBEY NAL - good results
No science just first hand experience of the old treatment.
Family member just had the old style operation - very bad dry eye - and the statement that this new technique avoids this - I believe it will have a future.brerwallabi said:
No science just first hand experience of the old treatment.
- Joined
- 6 November 2005
- Posts
- 915
- Reactions
- 0
Hi folks,
NAL ... this one is trading in accordance with the plan,
so far and is almost primed for a rally .....
Figure the lows were tested last week and we should
see some good news, around 08052006, possibly
detailing some long-tem strategies/changes for NAL.
Some key dates ahead, as NAL gains some
momentum, to the upside:
08052006 ... 3 significant and positive cycles here
22052006 ... negative news???
25052006 ... negative spotlight on NAL
01062006 ... positive - finances???
05062006 ... minor and positive news???
09062006 ... minor cycle?
26-27062006 ... 2 conflicting cycles here,
may result in flat trading ???
happy trading
yogi
- Joined
- 6 November 2005
- Posts
- 915
- Reactions
- 0
Hi folks,
NAL ..... ticked up on today's announcement
and more positive news/moves are expected
over the next week or so ..... see post above
for more key dates .....
happy days
yogi
- Joined
- 6 November 2005
- Posts
- 915
- Reactions
- 0
Hi folks,
NAL ..... comes in, right on time !~!
..... from post above, on 25042006:
"08052006 ... 3 significant and positive cycles here"
..... and today's news:
"Needle-free Commercial Strategic Update"
..... lifted NAL off its lows, with increased
volume, too ...
happy days
yogi
- Joined
- 6 November 2005
- Posts
- 915
- Reactions
- 0
Hi folks,
NAL ..... holding up well in the face of a general
slide in the markets, today .....
Next week, we may see NAL test its lows again, with
a couple of negative days expected, around:
22052006 ... negative news???
25052006 ... negative spotlight on NAL
01062006 ... positive - finances???
05062006 ... minor and positive news???
09062006 ... minor cycle?
26-27062006 ... 2 conflicting cycles here,
may result in flat trading ???
happy trading
yogi
- Joined
- 22 July 2006
- Posts
- 852
- Reactions
- 1
Guys
Anyone lucky enough to have caught the volume spike on this one and bought in a couple of days ago. I liked the look of this stock back at 6 cents, but had no capital to invest. Today its up to 15 cents. I mean, its been a bit of a dog for a little while, but the biotechs seem to be back in the good books with the punters....
Check out the chart!
Cheers
Anyone lucky enough to have caught the volume spike on this one and bought in a couple of days ago. I liked the look of this stock back at 6 cents, but had no capital to invest. Today its up to 15 cents. I mean, its been a bit of a dog for a little while, but the biotechs seem to be back in the good books with the punters....
Check out the chart!
Cheers
moses said:
Sure it been up there ($2.14) and down there(4.9c yes not typo), but it's not in my long term hold colum.
Today is a great day by most standards.
http://www.asx.com.au/asx/statistic...rchByCode&releasedDuringCode=W&issuerCode=NAL
SevenFX
- Joined
- 27 November 2006
- Posts
- 222
- Reactions
- 5
NAL holds 48.7mn shares in NIM (UK AIM) worth about AU$18mn...
That's 9.4c per NAL share...
Thus the new injection technology and everything else in the SP for about 3c atm...
Plenty of room for substantial upside....
It's been on CNBC News today and Bloomberg.....some overnight press comment would be very good for the SP.
EB
That's 9.4c per NAL share...
Thus the new injection technology and everything else in the SP for about 3c atm...
Plenty of room for substantial upside....
It's been on CNBC News today and Bloomberg.....some overnight press comment would be very good for the SP.
EB
G'day people,
I've got a confession to make.
I was stupid enough to buy this on one of its spikes(...er...um...14.5c),hoping to get in and out with a modest profit.
Didn't happen,so anyway i've held this for a few months,through .065 and back.
Any idea what's going on with their needle free injection thingy and what it could be worth to them?
Any feedback appreciated.
I've got a confession to make.
I was stupid enough to buy this on one of its spikes(...er...um...14.5c),hoping to get in and out with a modest profit.
Didn't happen,so anyway i've held this for a few months,through .065 and back.
Any idea what's going on with their needle free injection thingy and what it could be worth to them?
Any feedback appreciated.
NAL - NORWOOD ABBEY LTD
Up 79.07% This thing is breaking out big time!
Needlefree Injection Patent Granted
NEEDLEFREE INJECTION PATENT GRANTED
Medical technologies group Norwood Abbey Ltd [ASX:NAL] advises that the Australian Commissioner of Patents
has granted an additional patent to the Massachusetts Institute of Technology (‘MIT’), flowing from Norwood
Abbey’s research at MIT in Cambridge, Massachusetts. NAL has an exclusive world wide license over this patent
and all intellectual property flowing from its sponsored research at MIT.
The patent is Australian Patent number 2003272279 and titled “Measuring Properties of an Anatomical Body”
Overall, the patent, which has a substantial number of individual patent claims, covers the concept of measuring
the mechanical properties of the skin (eg thickness, resistance etc) The technology is aimed at assisting in the
measurement of the mechanical resistance of the skin of an individual so as to be able to adjust the force of a
needle-free injector with the aim of being able to inject a drug to any specific required depth. The claims cover not
only the skin but also internal body surfaces.
In the main, different drugs are optimally best delivered at a particular depth (tissue layer. Traditionally, the
administration of drugs via injections through the skin has, in respect to the ‘depth of delivery’, been relatively
imprecise. As a result, standard dosages have in many cases had to be greater than would optimally be desired.
The ability to deliver a drug, to an optimally controlled depth, has the potential to allow for a more efficacious
patient outcome and also the possibility of reductions in the dosages required.
In particular, the patent includes claims that are based upon a medical device or method that includes a sensor
that is configured to measure a property of an outer layer of an anatomical body surface (eg skin).
- The sensor includes a source probe configured to stimulate a local surface of an outer layer of
an anatomical body surface.
- The sensor also includes a detector configured to measure a response of the outer layer
resulting from source probe stimulation.
- A controller coupled to the source probe and the sensor drives the source probe using a tailored
stochastic resistance and determines the properties of the outer layer using the measured
response received by the detector.
- The sensor can be used with medical devices such as needle-free injectors and micro-needle
devices. A servo-controller coupled to the drug injector and the skin sensor, can be used to
adjust the injection pressure of the drug injector to selectively deliver the drug to the body
based on the skin properties.
The ability to control the delivery of a drug to a targeted depth is a significant development. The ability to deliver a
drug to a designated depth can both increase the efficacy of a drug, as well as possibly enable a decrease in the
amount of ‘drug’ needed to achieve the required therapeutic or prophylactic outcome.
While the technology was primarily developed as part of the ‘Needle-free Injection’ project, the patent may have
wider applications.
Norwood Abbey has an exclusive international license over the technology.
To find out more about the Norwood group, visit www.norwoodabbey.com
Up 79.07%
This thing is breaking out big time!Needlefree Injection Patent Granted
NEEDLEFREE INJECTION PATENT GRANTED
Medical technologies group Norwood Abbey Ltd [ASX:NAL] advises that the Australian Commissioner of Patents
has granted an additional patent to the Massachusetts Institute of Technology (‘MIT’), flowing from Norwood
Abbey’s research at MIT in Cambridge, Massachusetts. NAL has an exclusive world wide license over this patent
and all intellectual property flowing from its sponsored research at MIT.
The patent is Australian Patent number 2003272279 and titled “Measuring Properties of an Anatomical Body”
Overall, the patent, which has a substantial number of individual patent claims, covers the concept of measuring
the mechanical properties of the skin (eg thickness, resistance etc) The technology is aimed at assisting in the
measurement of the mechanical resistance of the skin of an individual so as to be able to adjust the force of a
needle-free injector with the aim of being able to inject a drug to any specific required depth. The claims cover not
only the skin but also internal body surfaces.
In the main, different drugs are optimally best delivered at a particular depth (tissue layer. Traditionally, the
administration of drugs via injections through the skin has, in respect to the ‘depth of delivery’, been relatively
imprecise. As a result, standard dosages have in many cases had to be greater than would optimally be desired.
The ability to deliver a drug, to an optimally controlled depth, has the potential to allow for a more efficacious
patient outcome and also the possibility of reductions in the dosages required.
In particular, the patent includes claims that are based upon a medical device or method that includes a sensor
that is configured to measure a property of an outer layer of an anatomical body surface (eg skin).
- The sensor includes a source probe configured to stimulate a local surface of an outer layer of
an anatomical body surface.
- The sensor also includes a detector configured to measure a response of the outer layer
resulting from source probe stimulation.
- A controller coupled to the source probe and the sensor drives the source probe using a tailored
stochastic resistance and determines the properties of the outer layer using the measured
response received by the detector.
- The sensor can be used with medical devices such as needle-free injectors and micro-needle
devices. A servo-controller coupled to the drug injector and the skin sensor, can be used to
adjust the injection pressure of the drug injector to selectively deliver the drug to the body
based on the skin properties.
The ability to control the delivery of a drug to a targeted depth is a significant development. The ability to deliver a
drug to a designated depth can both increase the efficacy of a drug, as well as possibly enable a decrease in the
amount of ‘drug’ needed to achieve the required therapeutic or prophylactic outcome.
While the technology was primarily developed as part of the ‘Needle-free Injection’ project, the patent may have
wider applications.
Norwood Abbey has an exclusive international license over the technology.
To find out more about the Norwood group, visit www.norwoodabbey.com
Similar threads
